Moxifloxacin is a recently developed fluoroquinolone antibiotic. It is rapi
dly absorbed following oral administration, reaching a mean peak drug plasm
a concentration (C-max) of approximately 3.56 mg/l within 2 h after a 400 m
g dose. The rate and extent of absorption are not significantly affected by
food or elevated gastric pH. Moxifloxacin binds weakly to plasma proteins
and penetrates well into most tissue and fluid compartments, with generally
higher drug concentrations in tissue and fluid compartments than those obs
erved in plasma. Moxifloxacin is metabolized to an N-sulfate conjugate and
an acyl glucuronide in humans. The N-sulfate and the unchanged moxifloxacin
are detected in plasma, urine and feces. The acyl-glucuronide is detected
in plasma and urine, but not in feces. The plasma elimination half-life ran
ges from 8.2-15.1 h in healthy individuals. The urinary excretion of the un
changed drug accounts for 19-22% of the given dose. Neither renal nor hepat
ic impairment significantly affect the pharmacokinetics of moxifloxacin. (C
)2000 Prous Science. Atl rights reserved.